Hepatitis D medical therapy

Revision as of 16:45, 16 October 2012 by Maheep Sangha (talk | contribs)
Jump to navigation Jump to search

Hepatitis Main Page

Hepatitis D

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hepatitis D from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Hepatitis D medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis D medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis D medical therapy

CDC on Hepatitis D medical therapy

Hepatitis D medical therapy in the news

Blogs on Hepatitis D medical therapy

Directions to Hospitals Treating Hepatitis D

Risk calculators and risk factors for Hepatitis D medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]

Overview

Medical Therapy

There is no specific available treatment. For persons with severe hepatitis, only supportive care is given. The treatment of chronic active hepatitis B and coexistent hepatitis D infection with alpha interferon would be done only after consultation and referral to a gastroenterologist.[1] Monitoring HDV RNA and serological levels of HBsAg may help in management of these patients.[2]

Follow-up for 6months may be recommended in these patients to evaluate for the development of chronic HBV and HDV infection.

References

  1. Center for Substance Abuse Treatment. Screening for Infectious Diseases Among Substance Abusers. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 1993. (Treatment Improvement Protocol (TIP) Series, No. 6.) Chapter 15 - Viral Hepatitis D.
  2. Manesis EK, Schina M, Le Gal F, Agelopoulou O, Papaioannou C, Kalligeros C, Arseniou V, Manolakopoulos S, Hadziyannis ES, Gault E, Koskinas J, Papatheodoridis G, Archimandritis AJ (2007). "Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring". Antiviral Therapy. 12 (3): 381–8. PMID 17591028. |access-date= requires |url= (help)

Template:WH Template:WS